SCHEMBL3882899

SCHEMBL3882899

CC(=O)N1CCC[C@@]1(O)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL468846 1.00 CYP3A4 (0.36) CYP3A4
Lactic Acid SCHEMBL15522845 0.89 TP53 (0.37) CYP3A4
SCHEMBL1966761 0.83
SCHEMBL8185651 0.81
SCHEMBL2544911 0.79 OPRM1 (0.34)
SCHEMBL1966290 0.77 CYP2C19 (0.30)
SCHEMBL1991499 0.76 JAK3 (0.32)
SCHEMBL15756820 0.76 DPP4 (0.38)
SCHEMBL10484687 0.76 L3MBTL1 (0.33)
SCHEMBL2682019 0.75 CYP3A4 (0.40) CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2124934-B1 COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACETYLHYDROXYPROLINE BEIERSDORF AG (DE) 2015-04-08 EP claimed
US-20140128468-A1 TOPICAL FILM-FORMING COMPOSITION, AND USE THEREOF FOR TREATING MYCOSES LABORATOIRES URGO (FR) 2014-05-08 US disclosed
CN-102046021-A Film coated compressed chewing gum FERTIN PHARMA AS 2011-05-04 CN disclosed
EP-1159952-B1 N-Acetylhydroxyproline for improving the moisture retention function of the epidermis KYOWA HAKKO KOGYO KK (JP) 2009-01-14 EP disclosed
EP-1660493-B1 PEPTIDYL HETEROCYCLIC KETONE DERIVATIVES AND PREPARATION PROCESSES JANSSEN PHARMACEUTICA NV (BE) 2008-10-08 EP disclosed
US-7291739-B2 3, 4-disubstituted pyridine compounds; IMPERIAL INNOVATIONS LIMITED (GB) 2007-11-06 US disclosed
EP-1660493-A1 PEPTIDYL HETEROCYCLIC KETONE DERIVATIVES AND PREPARATION PROCESSES JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-31 EP disclosed
WO-2005023804-A1 PEPTIDYL HETEROCYCLIC KETONE DERIVATIVES AND PREPARATION PROCESSES JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-17 WO disclosed
EP-0826773-B1 Process for producing trans-4-hydroxy-l-proline KYOWA HAKKO KOGYO KK (JP) 2005-01-26 EP disclosed
US-6743922-B2 3-SUBSTITUENT HIGHLY RESISTANT TO ROTATION-4-TERTIARY AMINO-PYRIDINE UNIVERSITY OF SHEFFIELD (GB) 2004-06-01 US disclosed
EP-0826773-A2 Process for producing trans-4-hydroxy-l-proline KYOWA HAKKO KOGYO CO., LTD. (JP) 1998-03-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140128468-A1 TOPICAL FILM-FORMING COMPOSITION, AND USE THEREOF FOR TREATING MYCOSES CUTA, NACA, DPM1 CYP3A4 3627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.